Featured Research

from universities, journals, and other organizations

Impulsivity, rewards and ritalin: Monkey study shows tighter link

Date:
November 13, 2013
Source:
University of Wisconsin-Madison
Summary:
Even as the rate of diagnosis has reached 11 percent among American children aged 4 to 17, neuroscientists are still trying to understand attention deficit hyperactivity disorder (ADHD). One classic symptom is impulsivity — the tendency to act before thinking.

A willingness to take a smaller reward right away rather than a larger, delayed reward is a common feature of ADHD.
Credit: paradox / Fotolia

Even as the rate of diagnosis has reached 11 percent among American children aged 4 to 17, neuroscientists are still trying to understand attention deficit hyperactivity disorder (ADHD). One classic symptom is impulsivity -- the tendency to act before thinking.

Scientifically, impulsivity can appear as a choice for a small but immediate reward over a larger one that requires some delay. Choosing between present and future rewards is a fundamental need in schooling, says Luis Populin, associate professor of neuroscience at University of Wisconsin-Madison. "If you say to an impulsive child, 'Do your homework so you will get a good grade at the end of the quarter,' that has less appeal than 'Let's play baseball this afternoon instead of studying chemistry.'"

To study impulsive behavior, Populin and graduate student Abigail Zdrale Rajala selected two rhesus macaque monkeys with opposite behaviors. One was extremely calm, while the other was nervous, fidgety and impulsive. The monkeys were trained to stare at a dot on a screen and, when it went dark, to choose between two pictures placed to the side. Their choice of picture determined whether they got a small but immediate sip of water, or a larger sip, after a delay ranging up to 16 seconds.

As expected, the calm monkey, but not the impulsive one, quickly figured out that waiting would bring the sweeter result.

This willingness to take a smaller reward right away rather than a larger, delayed reward, called "temporal discounting," is a common feature of "combined type" ADHD, which specifically lists impulsivity among its diagnostic criteria, Populin says.

When the monkeys were given a dose of methylphenidate, the active ingredient of the common ADHD drug Ritalin, they chose the delayed reward more frequently. The impulsive monkey actually showed the same preference for delayed rewards as the unmedicated, calm monkey. However, identifiable differences in their performance mean that methylphenidate improved the condition, but did not eliminate it.

"There is no perfect animal model of ADHD," says Rajala, "but many studies are performed on rodents; this one was done in a non-human primate, which is much closer to humans." The Society for Neuroscience adjudged the paper valuable enough to support Rajala's travel to the conference in San Diego.

Methylphenidate changes the elimination of dopamine, a "reward" neurotransmitter that is elevated by drugs like cocaine and amphetamine. The result is that more dopamine remains in the brain, which is the most likely explanation for the altered reward processing in the medicated monkeys.

Some scientists have thought that temporal discounting in ADHD may result from cognitive processing, which relies on the highly evolved frontal cortex in the brain. The new results support an alternative, but less common, hypothesis: that temporal discounting is linked to the reward-processing mechanism, which is governed by more primitive parts of the brain.

By teasing apart one characteristic of ADHD, the study could help refine drug or behavioral treatments of a disability that has grown 16 percent more common just since 2007, Populin says.


Story Source:

The above story is based on materials provided by University of Wisconsin-Madison. Note: Materials may be edited for content and length.


Cite This Page:

University of Wisconsin-Madison. "Impulsivity, rewards and ritalin: Monkey study shows tighter link." ScienceDaily. ScienceDaily, 13 November 2013. <www.sciencedaily.com/releases/2013/11/131113162341.htm>.
University of Wisconsin-Madison. (2013, November 13). Impulsivity, rewards and ritalin: Monkey study shows tighter link. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/11/131113162341.htm
University of Wisconsin-Madison. "Impulsivity, rewards and ritalin: Monkey study shows tighter link." ScienceDaily. www.sciencedaily.com/releases/2013/11/131113162341.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins